Angiodynamic Gross Profit

The latest gross profit for ANGO is $170M as of May 2026. That compares with $160M in the prior-year period — up 12.7% year over year. That is below the Healthcare sector average of $67B. Investors often review this figure alongside Angiodynamic's historical trend and sector peers before judging valuation or financial health.

Over the past year, ANGO's gross profit moved from $160M to $170M — a 12.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Angiodynamic's operating scale or balance-sheet position.

Against Healthcare companies, ANGO currently prints $170M for gross profit, while the sector average sits near $67B. That is roughly 99.7% below the sector mean. Large gaps often invite a closer look at Angiodynamic's growth, margins, and balance sheet.

A gross profit figure of $170M for ANGO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $67B. Explore the charts below for those layers of context.

After noting ANGO's gross profit ($170M), review year-over-year change from $160M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.